EHA 2017 | Can we work together on a global scale to defeat AML?
Wolfgang Hiddemann
• 22 Jun 2017
Wolfgang Hiddemann, MD, PhD, from Ludwig-Maximilians University, Munich, Germany, speaks to us about current issues in the treatment of acute myeloid leukemia (AML), namely the fact that many biologic subgroups of AML are too small to allow statistical analysis of a clinical trial on these subgroups. There is also the problem of various pharmaceutical companies governing different novel agents, as detailed by Prof. Hiddemann, and he envisions a future whereby companies, researchers and clinicians across the world may work together to defeat AML. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
